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Guidance by molecular selection improves the outcome of early 
phase treatment for gynecological (GYN) cancers 
 
Background: Patients (pts) with advanced gynecological (GYN) 
cancers have limited therapeutic options and the prognosis is poor. 
Early phase trials may be a suitable option for pts with good 
performance status. Increasingly, molecular characterisation guides 
pt selection for early phase trials. We sought to determine the 
outcome of GYN pts treated in a phase 1 unit and examined the role 
of molecular selection to inform therapeutic decision making. 
Methods: Medical records of all pts with a GYN malignancy treated 
within an early phase trial between 2010 and 2016 were reviewed. 
Data comprising patient and tumor characteristics, prior treatment, 
trial therapy and outcome were analysed. 
Results: 81 pts with a median age of 60 years (range 20-75) with a 
diagnosis of ovarian (OC, 54), endometrial (EC, 15) or cervical/vulval 
(CC, 12) cancer were identified. The median number of prior 
therapies for advanced disease was 3 (OC) and 2 (EC and CC) (overall 
range 1-6). 9 pts (11%) entered a second and 1 pt a third phase 1 
study on disease progression. Next Generation Sequencing (NGS) 
using a targeted panel was performed in 32 pts (40%) with an 
actionable mutation identified in 9 including; KRAS (3pts), PIK3CA 
(2pts) and EGFR (2pts). Germline BRCA (gBRCA) testing was 
performed in 35 OC pts (65%) with 24 gBRCA mutations identified. 
Pts were allocated, in order of priority, where available, to (1) a trial 
selected on the basis of NGS or gBRCA (‘genomic’ 35%), (2) a ‘tumor 
specific’ cohort within an early phase trial (15%) or (3) a ‘generic’ 
study (51%). For the whole cohort there was an overall response 
rate (ORR) of 18% with 41% stable disease (SD) and median 
progression free survival (PFS) and overall survival (OS) of 13 and 46 
weeks respectively. Outcomes were best for pts in the genomic 
group. Both PFS and OS were significantly longer with genomic 
selection (p < 0.01 for both, Mantel-cox test) with median PFS of 29.7, 
14.2, 8.0 weeks and OS of 84.1, 69.7, 33.6 weeks for genomics, tumor 
specific and generic studies respectively. The ORR was also greatest 
for the genomic cohort (32%) compared to the tumour specific (7%) 
and generic (11%) groups. 
Within the heavily pre-treated EC and CC cohorts there was an OS of 
30 and 42 weeks respectively. 24% of EC pts had an ORR with a 
further 24% with stable disease (SD). There was only 1 response 
(9%) in the CC cohort, however SD was seen in 64%. The OS for the 
OC was 55 weeks with an ORR of 20% and 46% SD. 
Conclusions: Early phase trials represent a good option for pts with 
advanced GYN malignancies. Whilst applicable to all GYN cancers, 
this is particularly relevant for EC and CC pts as standard treatment 
options are limited. For OC patients (median 3 prior lines of 
chemotherapy in this cohort) where standard treatment options 
exist, early access to phase 1 genomic trials may result in improved 
response rates and allow further standard options to be given 
subsequently. NGS is feasible in real time and may have a positive 
impact on outcome. 
